Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of ribavirin dose, vitamin D, and peginterferon alfa-2a on treatment response in chronic hepatitis C
KCT0000152Phase 4Not yet recruiting
- Sponsor
- Roche
- Start
- Aug 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ribavirin, vitamin d, interferon alfa in hepatitis C virus infection, sponsored by Roche. Planned start Aug 2011; status: not yet recruiting.
02
Drugs
ribavirinvitamin dinterferon alfa
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on KCT0000152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000152.